Loading...
Loading...
SAVA| Name | Value |
|---|---|
| Revenues | 2.3M |
| Cost of Revenue | 0.4M |
| Gross Profit | 2.0M |
| Operating Expense | 22.4M |
| Operating I/L | -22.8M |
| Other Income/Expense | 1.9M |
| Interest Income | 1.6M |
| Pretax | -20.9M |
| Income Tax Expense | 7.6M |
| Net Income/Loss | -20.9M |
Cassava Sciences, Inc. is a clinical stage biotechnology company focused on developing drugs for neurodegenerative diseases. Its lead therapeutic product candidate, simufilam, is a small molecule drug that has completed Phase 2b clinical trial. The company also has an investigational diagnostic product candidate, SavaDx, which is a blood-based biomarker/diagnostic designed to detect Alzheimer's disease.
